Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 21 studies | 28% ± 7% | |
conventional dendritic cell | 20 studies | 32% ± 15% | |
macrophage | 17 studies | 27% ± 14% | |
dendritic cell | 16 studies | 45% ± 18% | |
memory B cell | 14 studies | 23% ± 7% | |
naive B cell | 14 studies | 27% ± 8% | |
plasmacytoid dendritic cell | 9 studies | 25% ± 6% | |
myeloid cell | 9 studies | 21% ± 4% | |
microglial cell | 7 studies | 40% ± 13% | |
monocyte | 6 studies | 31% ± 9% | |
precursor B cell | 4 studies | 28% ± 4% | |
immature B cell | 4 studies | 25% ± 5% | |
pro-B cell | 3 studies | 25% ± 4% | |
mononuclear phagocyte | 3 studies | 19% ± 2% | |
non-classical monocyte | 3 studies | 16% ± 0% | |
alveolar macrophage | 3 studies | 40% ± 10% |
Insufficient scRNA-seq data for expression of CIITA at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 2276.48 | 89 / 89 | 80% | 5.85 | 724 / 901 |
lung | 100% | 5225.19 | 578 / 578 | 78% | 7.27 | 903 / 1155 |
breast | 100% | 2159.70 | 458 / 459 | 74% | 4.80 | 822 / 1118 |
esophagus | 97% | 1149.85 | 1406 / 1445 | 73% | 6.00 | 134 / 183 |
uterus | 98% | 1466.32 | 167 / 170 | 68% | 6.36 | 311 / 459 |
thymus | 98% | 1805.30 | 640 / 653 | 68% | 4.41 | 410 / 605 |
stomach | 91% | 1168.96 | 327 / 359 | 66% | 6.32 | 189 / 286 |
intestine | 95% | 2149.38 | 917 / 966 | 58% | 4.63 | 304 / 527 |
ovary | 66% | 468.27 | 118 / 180 | 80% | 7.71 | 344 / 430 |
pancreas | 58% | 475.23 | 191 / 328 | 83% | 5.96 | 148 / 178 |
bladder | 86% | 1103.33 | 18 / 21 | 55% | 3.93 | 275 / 504 |
prostate | 99% | 1728.29 | 242 / 245 | 39% | 1.53 | 197 / 502 |
skin | 72% | 986.02 | 1308 / 1809 | 64% | 6.61 | 301 / 472 |
adrenal gland | 99% | 1688.75 | 256 / 258 | 11% | 0.38 | 26 / 230 |
lymph node | 0% | 0 | 0 / 0 | 100% | 40.97 | 29 / 29 |
spleen | 100% | 8369.77 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 2285.39 | 1190 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 93% | 3838.92 | 864 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 9.68 | 40 / 45 |
liver | 64% | 391.29 | 145 / 226 | 25% | 1.17 | 100 / 406 |
blood vessel | 84% | 1100.74 | 1125 / 1335 | 0% | 0 | 0 / 0 |
brain | 35% | 323.37 | 926 / 2642 | 47% | 3.13 | 331 / 705 |
heart | 81% | 666.29 | 695 / 861 | 0% | 0 | 0 / 0 |
muscle | 39% | 228.32 | 310 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 14% | 0.61 | 11 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045348 | Biological process | positive regulation of MHC class II biosynthetic process |
GO_0032966 | Biological process | negative regulation of collagen biosynthetic process |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0045345 | Biological process | positive regulation of MHC class I biosynthetic process |
GO_0046597 | Biological process | negative regulation of viral entry into host cell |
GO_0034341 | Biological process | response to type II interferon |
GO_0006955 | Biological process | immune response |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0046677 | Biological process | response to antibiotic |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0016605 | Cellular component | PML body |
GO_0003677 | Molecular function | DNA binding |
GO_0140297 | Molecular function | DNA-binding transcription factor binding |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0016746 | Molecular function | acyltransferase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0005525 | Molecular function | GTP binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CIITA |
Protein name | Class II transactivator MHC class II transactivator (CIITA) (EC 2.3.1.-) (EC 2.7.11.1) Class II MHC mutant RJ2.2.5 (Class II major histocompatibility complex transactivator) Class II major histocompatibility complex transactivator |
Synonyms | MHC2TA |
Description | FUNCTION: Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter . Does not bind DNA . May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both PubMed:8402893, PubMed:7749984, . Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter . Also mediates enhanced MHC class I transcription; the promoter element requirements for CIITA-mediated transcription are distinct from those of constitutive MHC class I transcription, and CIITA can functionally replace TAF1 at these genes. Activates CD74 transcription . Exhibits intrinsic GTP-stimulated acetyltransferase activity . Exhibits serine/threonine protein kinase activity: can phosphorylate the TFIID component TAF7, the RAP74 subunit of the general transcription factor TFIIF, histone H2B at 'Ser-37' and other histones (in vitro) . Has antiviral activity against Ebola virus and coronaviruses, including SARS-CoV-2 . Induces resistance by up-regulation of the p41 isoform of CD74, which blocks cathepsin-mediated cleavage of viral glycoproteins, thereby preventing viral fusion . .; FUNCTION: [Isoform 3]: Exhibits dominant-negative suppression of MHC class II gene expression. . |
Accessions | A0A2R8YFU9 ENST00000324288.14 ENST00000381835.9 [P33076-3] ENST00000644232.1 ENST00000646979.1 A0A1B0GU01 ENST00000618207.4 ENST00000636238.1 A0A2R8Y7F5 ENST00000576601.1 P33076 Q29704 A0A087X2I7 I3L2P7 Q6LC19 I3L2E5 A0A1B0GUQ8 ENST00000571186.5 ENST00000618327.4 A0A0B4J1S1 ENST00000637439.1 |